Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%
Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brokerages turned more positive, citing robust international business, improving domestic growth and a strong product pipeline.
Full story
Read the full story at The Economic Times (India) ↗
Continue reading this story on The Economic Times (India), the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
